Rigel Pharmaceuticals, Inc

(NASDAQ:RIGL)

Latest On Rigel Pharmaceuticals, Inc (RIGL):

Date/Time Type Description Signal Details
2023-05-26 15:54 ESTNewsRigel Pharmaceuticals Shows Promise With Q1 Earnings: Tavalisse And Rezlidhia Drive GrowthN/A
2023-05-03 02:14 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.08 beats by $0.02, revenue of $26.07M beats by $2MN/A
2023-05-03 02:13 ESTNewsRigel Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-03 02:13 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q1 2023 Earnings Call TranscriptN/A
2023-05-02 01:42 ESTNewsRigel Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-04-27 09:21 ESTNewsRigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For ProfitabilityN/A
2023-04-04 02:31 ESTNewsRigel Pharma begun at neutral at Piper Sandler on value creation potentialN/A
2023-03-09 06:02 ESTNewsRigel Pharmaceuticals' Challenges Continue To Outweigh Potential UpsideN/A
2023-03-08 00:02 ESTNewsRigel Pharma, with beats on quarterly top and bottom lines, surges 19%N/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals GAAP EPS of $0.34 beats by $0.80, revenue of $120.24M beats by $27.04MN/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call PresentationN/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q4 2022 Earnings Call TranscriptN/A
2023-03-06 18:38 ESTNewsRigel Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-01-28 01:25 ESTNewsRigel Pharmaceuticals (RIGL) Investor Presentation - SlideshowN/A
2023-01-09 20:04 ESTNewsRigel Pharma rises as preliminary Q4 revenue above estimatesN/A
2022-12-31 03:48 ESTNewsRigel Pharmaceuticals: A Strong Finish To 2022 And A Potentially Transformative 2023N/A
2022-12-22 20:32 ESTNewsRigel launches leukemia therapy in U.S.N/A
2022-12-15 15:09 ESTNewsRigel extends gains as dosing starts in early-stage trial for blood cancer therapyN/A
2022-12-03 04:05 ESTNewsRigel upgraded at Citi on bullish outlook for new leukemia drugN/A
2022-12-02 10:34 ESTNewsRigel stock soars 40% on FDA approval of blood cancer drug RezlidhiaN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.11 beats by $0.03, revenue of $22.4M misses by $0.21MN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q3 2022 Earnings Call TranscriptN/A
2022-11-02 22:35 ESTNewsRigel Pharma gains as analysts play down setback for COVID-19 therapyN/A
2022-10-31 23:15 ESTNewsRigel Pharmaceuticals Provides An Opportunity For Investors Or An AcquirerN/A
2022-10-11 06:01 ESTNewsRigel cutting 16% of workforce after declining to file sNDA for fostamatinibN/A
2022-08-18 23:47 ESTNewsRigel Pharma adds ~7% to reach over two month highN/A
2022-08-04 01:22 ESTNewsRigel rises 17% on strong Q2 resultN/A
2022-08-03 10:19 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-03 10:19 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-02 20:22 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.08 beats by $0.04, revenue of $29.82M beats by $6.17MN/A
2022-08-02 05:27 ESTNewsRigel Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-06-10 02:16 ESTNewsRigel Pharma downgraded at several street firms following anemia study failureN/A
2022-06-09 00:09 ESTNewsRigel stock crashes 48% as fostamatinib fails phase 3 anemia studyN/A
2022-06-09 00:08 ESTNewsRigel cut to Neutral at Cantor Fitzgerald after trial miss wipes out half of stock valueN/A
2022-05-31 10:56 ESTNewsRigel Pharmaceuticals: A Status CheckN/A
2022-05-04 11:44 ESTNewsRigel Pharmaceuticals, Inc.'s (RIGL) CEO Raul Rodriguez on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-03 19:55 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.16 misses by $0.02, revenue of $16.74M misses by $0.8MN/A
2022-05-03 19:54 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-03 01:40 ESTNewsRigel Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-04-08 20:19 ESTNewsRigel Pharmaceuticals grants stock options to employeesN/A
2022-03-22 02:13 ESTNewsRigel Pharmaceuticals: Why The Stock Is On A RunN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.13 in-line, revenue of $20.41M misses by $0.79MN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call PresentationN/A
2022-02-28 17:57 ESTNewsRigel Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-02-01 13:56 ESTNewsRigel Pharmaceuticals: A Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety NetN/A
2022-01-11 00:53 ESTNewsRigel down as it expects slight decrease in products sales in Q4 compared to prior yearN/A
2021-12-22 03:23 ESTNewsRigel Pharma says its trial for bleeding disorder therapy met main goal in JapanN/A
2021-11-30 10:44 ESTNewsRigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects AliveN/A

About Rigel Pharmaceuticals, Inc (RIGL):

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

See Advanced Chart

General

  • Name Rigel Pharmaceuticals, Inc
  • Symbol RIGL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 169
  • Last Split Factor1:9
  • Last Split Date2003-06-25
  • Fiscal Year EndDecember
  • IPO Date2000-11-29
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.rigel.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 6.34
  • Price/Book (Most Recent Quarter) 20.39
  • Enterprise Value Revenue 6.22
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.02
  • Next Year EPS Estimate -$0.20
  • Next Quarter EPS Estimate -$0.03
  • Profit Margin -27%
  • Operating Margin -27%
  • Return on Assets -14%
  • Return on Equity -68%
  • Revenue 108.62 million
  • Earnings Per Share -$0.35
  • Revenue Per Share $0.64
  • Gross Profit 47.63 million
  • Quarterly Earnings Growth 19.8%
View More

Highlights

  • Market Capitalization 689.52 million
  • EBITDA -60896000
  • PE Ratio -16.62
  • PEG Ratio -0.1
  • Analyst Target Price $8.5
  • Book Value Per Share $0.20
View More

Share Statistics

  • Shares Outstanding 170.04 million
  • Shares Float 169.52 million
  • % Held by Insiders 31%
  • % Held by Institutions 85.26%
  • Shares Short 16.81 million
  • Shares Short Prior Month 19.36 million
  • Short Ratio 3.15
  • Short % of Float 11%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 1.45
  • 52 Week High $5.5
  • 52 Week Low $1.26
  • 50 Day Moving Average 4.2
  • 200 Day Moving Average 3.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Rigel Pharmaceuticals, Inc (RIGL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Rigel Pharmaceuticals, Inc (RIGL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-02$18.45 million-$0.11-$0.113.51%
2020-09-302020-11-05$18.39 million-$0.08-$0.1234.05%
2020-06-302020-08-04$16.02 million-$0.10-$0.1426.09%
2020-03-312020-05-05$55.76 million$0.13$0.13-1.59%
2019-12-312020-02-27$15.4 million-$0.10-$0.1217.56%
2019-09-302019-11-05$20.86 million-$0.07-$0.1032.69%
2019-06-302019-08-06$10.41 million-$0.12-$0.1412.22%
2019-03-312019-05-07$12.62 million-$0.11-$0.1315.38%
2018-12-312019-02-28$37.86 million$0.02$0.03-41.35%
2018-09-302018-11-06$4.87 million-$0.14-$0.157.83%
2018-06-302018-08-08$1.79 million-$0.16-$0.16-0.19%
2018-03-312018-05-01$N/A-$0.17-$0.183.41%
2017-12-312018-03-06$3.58 million-$0.18-$0.13-35.03%
2017-09-302017-11-07$900000-$0.14-$0.158.32%
2017-06-302017-08-01$-3584000-$0.16-$0.14-12.76%
2017-03-312017-05-02$3.58 million-$0.13-$0.12-5.18%
2016-12-312017-03-07$3 million-$0.16-$0.175.33%
2016-09-302016-11-01$3.76 million-$0.24-$0.23-3.99%
2016-06-302016-08-02$8.59 million-$0.15-$0.2026.33%
2016-03-312016-05-03$5.03 million-$0.19-$0.219.18%
2015-12-312016-03-08$8.54 million-$0.14-$0.14-3.47%
2015-09-302015-11-03$13 million-$0.08-$0.1752.94%
2015-06-302015-08-04$5.18 million-$0.16-$0.2227.27%
2015-03-312015-05-07$2.18 million-$0.21-$0.18-16.67%
2014-12-312015-03-03$8.25 million-$0.15-$0.2642.31%
2014-09-302014-11-04$N/A-$0.24-$0.2711.11%
2014-06-302014-08-05$N/A-$0.29-$0.25-16%
2014-03-312014-05-07$N/A-$0.25-$0.250%
2013-12-312014-03-04$5.75 million-$0.19-$0.2524%
2013-09-302013-11-05$-1400000-$0.25-$0.2913.79%
2013-06-302013-08-06$1.4 million-$0.26-$0.3013.33%
2013-03-312013-05-07$N/A-$0.29-$0.303.33%
2012-12-312013-03-05$2.25 million-$0.30-$0.326.25%
2012-09-302012-11-06$-1500000-$0.36-$0.372.7%
2012-06-302012-08-07$1.5 million-$0.35-$0.350%
2012-03-312012-05-01$750000-$0.32-$0.31-3.23%
2011-12-312012-03-06$395000-$0.36-$0.28-28.57%
2011-09-302011-11-01$4.36 million-$0.25-$0.3016.67%
2011-06-302011-08-02$395000-$0.37-$0.382.63%
2011-03-312011-05-03$N/A-$0.40-$0.36-11.11%
2010-12-312011-03-01$52.72 million-$0.33-$0.368.33%
2010-09-302010-11-02$72.28 million$0.96$0.6254.84%
2010-06-302010-08-03$49.46 million$0.51$0.478.51%
2010-03-312010-05-04$3.26 million-$0.43$0.11-490.91%
2009-12-312010-03-02$750000-$0.48-$0.45-6.67%
2009-09-302009-11-03$N/A-$0.70-$0.58-20.69%
2009-06-302009-08-04$N/A-$0.81-$0.810%
2009-03-312009-05-05$N/A-$0.82-$0.9917.17%
2008-12-312009-02-24$N/A-$0.91-$0.976.19%
2008-09-302008-11-03$N/A-$1.03-$0.87-18.39%
2008-06-302008-08-05$N/A-$0.93-$0.69-34.78%
2008-03-312008-05-06$N/A-$0.79-$0.62-27.42%
2007-12-312008-02-12$8 million-$0.61-$0.43-41.86%
2007-09-302007-11-06$-1956000-$0.61-$0.57-7.02%
2007-06-302007-08-07$1.96 million-$0.68-$0.63-7.94%
2007-03-312007-05-10$2.64 million-$0.68-$0.67-1.49%
2006-12-312007-02-06$3.13 million-$0.62-$0.643.13%
2006-09-302006-11-07$6.13 million-$0.46-$0.472.13%
2006-06-302006-08-02$14.32 million-$0.09-$0.5683.93%
2006-03-312006-05-02$9.9 million-$0.34-$0.32-6.25%
2005-12-312006-02-07$6.02 million-$0.36-$0.4316.28%
2005-09-302005-11-08$3.28 million-$0.56-$0.618.2%
2005-06-302005-08-03$4.61 million-$0.62-$0.7112.68%
2005-03-312005-05-03$2.62 million-$0.57-$0.48-18.75%
2004-12-312005-02-08$1.1 million-$0.75-$0.69-8.7%
2004-09-302004-11-05$659000-$0.88-$0.71-23.94%
2004-06-302004-08-03$1.49 million-$0.68-$0.748.11%
2004-03-312004-05-04$1.49 million-$0.81-$0.78-3.85%
2003-12-312004-02-03$2.11 million-$0.80-$0.71-12.68%
2003-09-302003-11-05$2.1 million-$0.78
2003-06-302003-08-05$2.35 million-$1.90
2003-03-312003-05-06$4.5 million-$1.53
2002-12-312003-02-05$3.7 million-$1.62-$2.1625%
2002-09-302002-11-04$3.65 million-$1.98-$1.80-10%
2002-06-302002-08-06$4.34 million-$2.07-$1.35-53.33%
2002-03-312002-05-07$4.1 million-$1.71-$1.53-11.76%
2001-12-312002-02-05$4.78 million-$1.44-$1.8421.74%
2001-09-302001-11-07$4.21 million-$1.53-$1.530%
2001-06-302001-08-08$3.12 million-$1.80-$0.99-81.82%
2001-03-312001-05-08$3.19 million-$0.99-$1.4431.25%
2000-12-312001-02-07$3.21 million-$3.24-$2.34-38.46%

Rigel Pharmaceuticals, Inc (RIGL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Rigel Pharmaceuticals, Inc (RIGL) Chart:

Rigel Pharmaceuticals, Inc (RIGL) News:

Below you will find a list of latest news for Rigel Pharmaceuticals, Inc (RIGL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Rigel Pharmaceuticals, Inc (RIGL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-04-17110CALL0 0185.91TRUE00
2025-04-17120CALL0 0173.29TRUE00
2025-04-17130CALL0 074.73TRUE00
2025-04-17140CALL0 098.85TRUE00
2025-04-17152.05CALL0 293.1TRUE00
2025-04-17162.85CALL0 2145.24TRUE00
2025-04-17171.3CALL0 7164.4TRUE00
2025-04-17181.2CALL0 1177.23FALSE00
2025-04-17190.7CALL0 5285.78FALSE00
2025-04-17200.48CALL0 26281.74FALSE00
2025-04-17210.49CALL0 8229.2FALSE00
2025-04-17220.05CALL0 31252.31FALSE00
2025-04-17230.25CALL0 9190.18FALSE00
2025-04-17240.4CALL0 2191.65FALSE00
2025-04-17250.72CALL0 3252.01FALSE00
2025-04-17260CALL0 0327.71FALSE00
2025-04-17270.1CALL0 17343.52FALSE00
2025-04-17280CALL0 0358.4FALSE00
2025-04-17290.65CALL0 1372.48FALSE00
2025-04-17300.01CALL0 10167.03FALSE00
2025-04-17110PUT0 0151.25FALSE00
2025-04-17120PUT0 0359.39FALSE00
2025-04-17130PUT0 0309.04FALSE00
2025-04-17140PUT0 0277.31FALSE00
2025-04-17150PUT0 0335.5FALSE00
2025-04-17160.55PUT5 6108.98FALSE0.550
2025-04-17170.4PUT0 3699.59FALSE00
2025-04-17181.65PUT3 21120.68TRUE1.650
2025-04-17192.73PUT0 1075.9TRUE00
2025-04-17202.1PUT0 2309.11TRUE00
2025-04-17211.95PUT0 780.28TRUE00
2025-04-17224.5PUT0 31371.03TRUE00
2025-04-17230PUT0 0393.71TRUE00
2025-04-17240PUT0 0404.55TRUE00
2025-04-17250PUT0 0116.8TRUE00
2025-04-17264.9PUT0 0442.07TRUE00
2025-04-17270PUT0 0459.08TRUE00
2025-04-17280PUT0 0475.11TRUE00
2025-04-17290PUT0 0490.26TRUE00
2025-04-17300PUT0 0504.63TRUE00
2025-05-16110CALL0 0113.17TRUE00
2025-05-16120CALL0 0106.11TRUE00
2025-05-16130CALL0 0100.96TRUE00
2025-05-16140CALL0 086.21TRUE00
2025-05-16150CALL0 090.06TRUE00
2025-05-16162.98CALL0 291.06TRUE00
2025-05-16170CALL0 0100.78TRUE00
2025-05-16180CALL0 0122.42FALSE00
2025-05-16192.25CALL0 580.16FALSE00
2025-05-16201.4CALL0 30118.53FALSE00
2025-05-16210CALL0 0165.75FALSE00
2025-05-16221.55CALL0 18142.25FALSE00
2025-05-16230CALL0 0139.05FALSE00
2025-05-16240.96CALL0 2190.64FALSE00
2025-05-16251.1CALL0 1156.94FALSE00
2025-05-16260.28CALL0 6191.3FALSE00
2025-05-16271.02CALL0 1169.89FALSE00
2025-05-16280CALL0 0166FALSE00
2025-05-16290CALL0 0172.56FALSE00
2025-05-16110PUT0 0278.54FALSE00
2025-05-16120PUT0 0242.91FALSE00
2025-05-16130PUT0 0216.52FALSE00
2025-05-16140PUT0 0197.26FALSE00
2025-05-16151.25PUT1 0109.27FALSE1.250
2025-05-16161.25PUT0 1173.6FALSE00
2025-05-16170PUT0 0125.61FALSE00
2025-05-16180PUT0 096.47TRUE00
2025-05-16193.52PUT0 2092.23TRUE00
2025-05-16200PUT0 082.04TRUE00
2025-05-16210PUT0 077.54TRUE00
2025-05-16220PUT0 081.35TRUE00
2025-05-16230PUT0 086.84TRUE00
2025-05-16240PUT0 083.15TRUE00
2025-05-16250PUT0 062.85TRUE00
2025-05-16260PUT0 068.32TRUE00
2025-05-16270PUT0 073.54TRUE00
2025-05-16280PUT0 0224TRUE00
2025-05-16290PUT0 0231.19TRUE00
2025-06-2030CALL0 0206.62TRUE00
2025-06-2050CALL0 0140.43TRUE00
2025-06-2070CALL0 0114.71TRUE00
2025-06-20811.9CALL0 8130.14TRUE00
2025-06-2098CALL0 192.13TRUE00
2025-06-20107.7CALL0 691.11TRUE00
2025-06-20110CALL0 094.62TRUE00
2025-06-20120CALL0 086.88TRUE00
2025-06-20136.63CALL0 093.96TRUE00
2025-06-20146.35CALL0 788.59TRUE00
2025-06-20154.2CALL0 1895.34TRUE00
2025-06-20165.3CALL0 187.17TRUE00
2025-06-20172.6CALL5 1979.56TRUE2.60
2025-06-20183.7CALL0 283.52FALSE00
2025-06-20193CALL0 998.58FALSE00
2025-06-20201.7CALL0 12108.87FALSE00
2025-06-20215.05CALL0 3118.05FALSE00
2025-06-20224.19CALL0 1101.26FALSE00
2025-06-20233.3CALL0 9133.98FALSE00
2025-06-20246CALL0 3139.34FALSE00
2025-06-20250.8CALL0 34120.01FALSE00
2025-06-20262.72CALL0 6127.68FALSE00
2025-06-20271.4CALL0 77125.89FALSE00
2025-06-20287.2CALL0 2161.31FALSE00
2025-06-20290CALL0 0166.38FALSE00
2025-06-20300.22CALL0 3582.6FALSE00
2025-06-20310CALL0 0172.26FALSE00
2025-06-20320CALL0 0156.65FALSE00
2025-06-20330CALL0 0150.03FALSE00
2025-06-20340CALL0 0191.74FALSE00
2025-06-20350.21CALL0 5157.44FALSE00
2025-06-20361.45CALL0 1150.43FALSE00
2025-06-20370.2CALL0 11153.71FALSE00
2025-06-20380.41CALL0 26156.86FALSE00
2025-06-20400.05CALL0 1178.26FALSE00
2025-06-2030PUT0 0452.75FALSE00
2025-06-2050PUT0 0313.26FALSE00
2025-06-2070PUT0 0236.08FALSE00
2025-06-2080PUT0 0295.93FALSE00
2025-06-2090PUT0 0197.57FALSE00
2025-06-20100PUT0 0226.33FALSE00
2025-06-20110PUT0 0203.25FALSE00
2025-06-20120.4PUT0 4182.22FALSE00
2025-06-20130PUT0 0162.76FALSE00
2025-06-20140.96PUT0 1142.42FALSE00
2025-06-20151.05PUT0 11123.14FALSE00
2025-06-20162PUT0 1986.77FALSE00
2025-06-20171.95PUT0 1381.05FALSE00
2025-06-20181.93PUT0 185.97TRUE00
2025-06-20193.8PUT0 284TRUE00
2025-06-20205.3PUT0 377.74TRUE00
2025-06-20213.2PUT0 776.32TRUE00
2025-06-20220PUT0 076.85TRUE00
2025-06-20235.3PUT0 480TRUE00
2025-06-20240PUT0 068.26TRUE00
2025-06-20257.5PUT0 078.91TRUE00
2025-06-20260PUT0 078.95TRUE00
2025-06-20270PUT0 077.67TRUE00
2025-06-20280PUT0 061.79TRUE00
2025-06-20290PUT0 065.47TRUE00
2025-06-20300PUT0 082.49TRUE00
2025-06-20310PUT0 080.85TRUE00
2025-06-20320PUT0 0186.12TRUE00
2025-06-20330PUT0 0190.47TRUE00
2025-06-20340PUT0 0194.64TRUE00
2025-06-20350PUT0 0198.65TRUE00
2025-06-20360PUT0 0202.5TRUE00
2025-06-20370PUT0 0206.21TRUE00
2025-06-20380PUT0 0209.79TRUE00
2025-06-20400PUT0 0216.58TRUE00
2025-09-1930CALL0 0466.95TRUE00
2025-09-1950CALL0 0106.22TRUE00
2025-09-1990CALL0 092.27TRUE00
2025-09-19100CALL0 098.6TRUE00
2025-09-19110CALL0 089.53TRUE00
2025-09-19120CALL0 091.12TRUE00
2025-09-19139.5CALL0 490.82TRUE00
2025-09-19140CALL0 082.37TRUE00
2025-09-19150CALL0 086.72TRUE00
2025-09-19167.2CALL0 1081.02TRUE00
2025-09-19170CALL0 081.74TRUE00
2025-09-19184CALL0 081.49FALSE00
2025-09-19192.95CALL0 398.61FALSE00
2025-09-19205.01CALL1 2128.46FALSE5.010
2025-09-19215CALL1 278.27FALSE50
2025-09-19221.8CALL2 1769.49FALSE-0.3-0.14
2025-09-19231.75CALL1 6573.35FALSE-0.25-0.13
2025-09-19241.91CALL0 2179.09FALSE00
2025-09-19251.75CALL0 8273.92FALSE00
2025-09-19300.85CALL0 5283.9FALSE00
2025-09-19352CALL0 2113.44FALSE00
2025-09-1930PUT0 0514.97FALSE00
2025-09-1950PUT0 0309.22FALSE00
2025-09-1990.4PUT0 2177.74FALSE00
2025-09-19100PUT0 0157.8FALSE00
2025-09-19110PUT0 0140.19FALSE00
2025-09-19120PUT0 0124.34FALSE00
2025-09-19132PUT0 2113.49FALSE00
2025-09-19142.5PUT0 299.71FALSE00
2025-09-19152.5PUT0 2287.34FALSE00
2025-09-19162.03PUT0 185.55FALSE00
2025-09-19173.09PUT0 584.09FALSE00
2025-09-19183.9PUT0 1081.82TRUE00
2025-09-19193.7PUT0 279.89TRUE00
2025-09-19200PUT0 078.31TRUE00
2025-09-19210PUT0 080.37TRUE00
2025-09-19220PUT0 077.35TRUE00
2025-09-19230PUT0 075.85TRUE00
2025-09-19240PUT0 077.19TRUE00
2025-09-19250PUT0 075.6TRUE00
2025-09-19300PUT0 069.88TRUE00
2025-09-19350PUT0 064.45TRUE00

Latest RIGL Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST100$0.6924
Jun 13, 2022 7:59 PM EST200$0.6924
Jun 13, 2022 7:59 PM EST100$0.6924
Jun 13, 2022 7:59 PM EST500$0.6924
Jun 13, 2022 7:59 PM EST850$0.6921

Rigel Pharmaceuticals, Inc (RIGL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006136/0001179110-20-006136-index.htm
2019-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000021545719005836/0000215457-19-005836-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000031506619001306/0000315066-19-001306-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000031506620001146/0000315066-20-001146-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000083423720006820/0000834237-20-006820-index.htm
2020-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000083423720009960/0000834237-20-009960-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000090221919000369/0000902219-19-000369-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000090221920000160/0000902219-20-000160-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000093041319000568/0000930413-19-000568-index.htm
2019-04-09DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1034842/000104746919002080/0001047469-19-002080-index.htm
2020-04-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1034842/000104746920001990/0001047469-20-001990-index.htm
2020-05-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000104746920002759/0001047469-20-002759-index.htm
2020-08-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1034842/000104746920004389/0001047469-20-004389-index.htm
2018-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918034498/0001104659-18-034498-index.htm
2018-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918037232/0001104659-18-037232-index.htm
2018-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918050532/0001104659-18-050532-index.htm
2018-08-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465918050560/0001104659-18-050560-index.htm
2018-10-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918060459/0001104659-18-060459-index.htm
2018-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918064285/0001104659-18-064285-index.htm
2018-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918066323/0001104659-18-066323-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919001118/0001104659-19-001118-index.htm
2019-01-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919002845/0001104659-19-002845-index.htm
2019-02-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919005217/0001104659-19-005217-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919011582/0001104659-19-011582-index.htm
2019-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919017440/0001104659-19-017440-index.htm
2019-04-09DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000110465919020480/0001104659-19-020480-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919027507/0001104659-19-027507-index.htm
2019-05-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919029862/0001104659-19-029862-index.htm
2019-05-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919031798/0001104659-19-031798-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919044305/0001104659-19-044305-index.htm
2019-08-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465919044376/0001104659-19-044376-index.htm
2019-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919052388/0001104659-19-052388-index.htm
2019-10-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919055689/0001104659-19-055689-index.htm
2019-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919060054/0001104659-19-060054-index.htm
2019-11-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919065084/0001104659-19-065084-index.htm
2019-11-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919066635/0001104659-19-066635-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919073467/0001104659-19-073467-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920003446/0001104659-20-003446-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000110465920016449/0001104659-20-016449-index.htm
2020-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920026180/0001104659-20-026180-index.htm
2020-04-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000110465920041947/0001104659-20-041947-index.htm
2020-05-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920056879/0001104659-20-056879-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920062621/0001104659-20-062621-index.htm
2020-08-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920090262/0001104659-20-090262-index.htm
2020-08-04S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465920090388/0001104659-20-090388-index.htm
2020-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920113467/0001104659-20-113467-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920121776/0001104659-20-121776-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006680/0001179110-18-006680-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006681/0001179110-18-006681-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006682/0001179110-18-006682-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007148/0001179110-18-007148-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007149/0001179110-18-007149-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007150/0001179110-18-007150-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007151/0001179110-18-007151-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007152/0001179110-18-007152-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007153/0001179110-18-007153-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007154/0001179110-18-007154-index.htm
2018-06-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018008174/0001179110-18-008174-index.htm
2018-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018008176/0001179110-18-008176-index.htm
2018-07-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018009506/0001179110-18-009506-index.htm
2018-08-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010636/0001179110-18-010636-index.htm
2018-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010749/0001179110-18-010749-index.htm
2018-08-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010936/0001179110-18-010936-index.htm
2018-09-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018012211/0001179110-18-012211-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000931/0001179110-19-000931-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000932/0001179110-19-000932-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000933/0001179110-19-000933-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000934/0001179110-19-000934-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000935/0001179110-19-000935-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000936/0001179110-19-000936-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000938/0001179110-19-000938-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000939/0001179110-19-000939-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000940/0001179110-19-000940-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004205/0001179110-19-004205-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004206/0001179110-19-004206-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004207/0001179110-19-004207-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004208/0001179110-19-004208-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004209/0001179110-19-004209-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004210/0001179110-19-004210-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004211/0001179110-19-004211-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004212/0001179110-19-004212-index.htm
2019-04-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004736/0001179110-19-004736-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004740/0001179110-19-004740-index.htm
2019-05-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006694/0001179110-19-006694-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006698/0001179110-19-006698-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006699/0001179110-19-006699-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006700/0001179110-19-006700-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006701/0001179110-19-006701-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006702/0001179110-19-006702-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006703/0001179110-19-006703-index.htm
2019-11-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011701/0001179110-19-011701-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011937/0001179110-19-011937-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011938/0001179110-19-011938-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011940/0001179110-19-011940-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011942/0001179110-19-011942-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011944/0001179110-19-011944-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011946/0001179110-19-011946-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011948/0001179110-19-011948-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001348/0001179110-20-001348-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001349/0001179110-20-001349-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001350/0001179110-20-001350-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001351/0001179110-20-001351-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006129/0001179110-20-006129-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006130/0001179110-20-006130-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006131/0001179110-20-006131-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006132/0001179110-20-006132-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006133/0001179110-20-006133-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006134/0001179110-20-006134-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006135/0001179110-20-006135-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006136/0001179110-20-006136-index.htm
2020-08-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020009204/0001179110-20-009204-index.htm
2020-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020009207/0001179110-20-009207-index.htm
2019-11-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000131924419000084/0001319244-19-000084-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000131924420000054/0001319244-20-000054-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837018006758/0001558370-18-006758-index.htm
2018-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837018008624/0001558370-18-008624-index.htm
2019-02-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1034842/000155837019001310/0001558370-19-001310-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019004244/0001558370-19-004244-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019007232/0001558370-19-007232-index.htm
2019-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019009974/0001558370-19-009974-index.htm
2020-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1034842/000155837020001624/0001558370-20-001624-index.htm
2020-05-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020005179/0001558370-20-005179-index.htm
2020-08-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020009154/0001558370-20-009154-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020012838/0001558370-20-012838-index.htm
2019-03-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999719001548/9999999997-19-001548-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000137/9999999997-20-000137-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000138/9999999997-20-000138-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000139/9999999997-20-000139-index.htm
2020-02-05SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000517/9999999997-20-000517-index.htm
2020-02-18SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000741/9999999997-20-000741-index.htm
2020-04-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720002114/9999999997-20-002114-index.htm
2020-04-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720002115/9999999997-20-002115-index.htm

Rigel Pharmaceuticals, Inc (RIGL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Rigel Pharmaceuticals, Inc (RIGL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 31%
Institutional Ownership: 8526%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-07-02Anne-Marie DuliegeEVP & Chief Medical OfficerSell5,000.002.7913,932.000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018009506/0001179110-18-009506-index.htm
2018-09-04Anne-Marie DuliegeEVP & Chief Medical OfficerSell16,500.003.5157,860.550.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerSell115,500.003.50404,250.000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-08-23Eldon C. III MayerEVP & Chief Commercial OfficerBuy100,000.002.82282,320.00115,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018010936/0001179110-18-010936-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerBuy115,500.002.54293,370.00115,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-09-04Anne-Marie DuliegeEVP & Chief Medical OfficerBuy16,500.002.5441,910.0016,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-10Eldon C. III MayerEVP & Chief Commercial OfficerBuy50,000.003.28164,210.00165,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-08-17RAUL R RODRIGUEZCEO, PresidentBuy114,000.002.63300,002.40173,519.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018010749/0001179110-18-010749-index.htm
2018-09-11Eldon C. III MayerEVP & Chief Commercial OfficerBuy50,000.003.23161,340.00215,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerBuy37,500.002.1179,125.0037,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2019-05-22Dean L SchornoEVP &Chief Financial OfficerBuy46,726.002.1399,573.1146,726.00https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2019-05-22Dean L SchornoEVP &Chief Financial OfficerBuy3,274.002.136,971.0050,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2018-10-12Nelson CabatuanPrincipal Accounting OfficerSell10,000.003.1231,200.0058.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018012211/0001179110-18-012211-index.htm